Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis

References

• Vassiliou G, Green A R. Myeloproliferative disorders. Postgraduate Haematology5th ed, A V Hoffbrand, D Catovsky, E GD Tuddenham. Blackwell Publishing, Oxford 2005; 761–782
   Google Scholar
• Sanchez S, Ewton A. Essential thrombocythemia. A review of diagnostic and pathologic features. Arch Pathol Lab Med 2006; 130: 1144–1150
   PubMed Web of Science ®Google Scholar
• Tefferi A. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview. Mayo Clin Proc 1998; 73: 1177–1184
   PubMed Web of Science ®Google Scholar
• Elliott M A, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275–290
   PubMed Web of Science ®Google Scholar
• Schafer A I. Essential thrombocythemia and thrombocytosis. Williams Hematology7th ed, M A Lichtman, E Beutler, T J Kipps, U Seligsohn, K Kaushansky, J T Prchal. McGraw-Hill Medical. 2006; 1785–1794
   Google Scholar
• van Wolferen S A, Grunberg K, Noordegraaf A V. Diagnosis and management of pulmonary hypertension over the past 100 years. Respir Med 2007; 101: 389–398
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galié N, Rubin L J, Langleben D, Seeger W, Domenighetti G, et al. A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S–12S
   PubMed Web of Science ®Google Scholar
• Rubin L J. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111
   PubMed Web of Science ®Google Scholar
• Nands S, Orfei E. Pulmonary hypertension in polycythemia vera. Am J Hematol 1994; 47: 242–244
   PubMed Web of Science ®Google Scholar
• Ito H, Adachi Y, Arimura Y, Endo T, Hinoda Y, Imai K. A 25-year clinical history of portopulmonary hypertension associated with latent myeloproliferative disorder. J Gastroenterol 2003; 38: 488–492
   PubMed Web of Science ®Google Scholar
• Gupta R, Perumandla S, Patsiornik Y, Niranjan S, Ohri A. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. J Natl Med Assoc 2006; 98: 1779–1782
   PubMed Web of Science ®Google Scholar
• Marvin K S, Spellberg R D. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. Chest 1993; 103: 642–644
   PubMed Web of Science ®Google Scholar
• Koh K H, Cho S K, Kim S S, Oh B H, Lee W Y. Coronary vasospasm, multiple coronary thrombosis, unstable angina and essential thrombocytosis. Int J Cardiol 1993; 41: 168–170
   PubMed Web of Science ®Google Scholar
• Matsuyama N, Asada K, Kondo K, Kodama T, Minohara S, Hasegawa S, et al. Surgical treatment of aortic stenosis with polycythemia vera: a case report. Kyobu Geka 1996; 49: 1097–1099
   PubMedGoogle Scholar
• Nonami Y, Sasahashi N, Satoh K, Ogoshi S, Tamiya T. A case report: mitral valve replacement for the patient with essential thrombocythemia. Nippon Kyobu Geka Gakkai Zasshi 1993; 41: 1567–1572
   PubMedGoogle Scholar
• Thiele J, Kvasnicka H M. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003; 82: 148–152
   PubMed Web of Science ®Google Scholar
• Harrison C N. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005; 130: 153–165
   PubMed Web of Science ®Google Scholar
• Halank M, Marx C, Baretton G, Müller K -M, Ehninger G, Höffken G. Severe pulmonary hypertension in chronic idiopathic myelofibrosis. Onkologie 2004; 27: 472–474
   PubMed Web of Science ®Google Scholar
• Garcia-Monero G, Schuster S J, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 1999; 60: 130–135
   PubMed Web of Science ®Google Scholar
• Dan K. Thrombocytosis in iron deficiency anemia. Intern Med 2005; 44: 1025–1026
   PubMed Web of Science ®Google Scholar
• Nagai T, Komatsu N, Sakata Y, Miura Y, Ozawa K. Iron deficiency anemia with marked thrombocytosis complicated by central retinal vein occlusion. Intern Med 2005; 44: 1090–1092
   PubMed Web of Science ®Google Scholar
• Keung Y K, Owen J. Iron deficiency and thrombosis: literature review. Clin Appl Thromb Hemost 2004; 10: 387–391
   PubMed Web of Science ®Google Scholar
• Akins P T, Glenn S, Nemeth P M, Derdeyn C P. Carotid artery thrombus associated with severe ıron deficiency anemia and thrombocytosis. Stroke 1996; 27: 1002–1005
   PubMed Web of Science ®Google Scholar
• Dingli D, Utz J P, Krowka M J, Oberg A L, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001; 120: 801–808
   PubMed Web of Science ®Google Scholar
• Garypidou V, Vakalopoulou S, Dimitriadis D, Tziomalos K, Sfikas G, Perifanis V. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. Haematologica 2004; 89: 245–247
   PubMed Web of Science ®Google Scholar
• Michiels J J. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. Pathol Biol 2003; 51: 167–175
   PubMed Web of Science ®Google Scholar
• Haznedaroğlu I C, Atalar E, Ozturk M A, Ozer N, Ovunc K, Aksoyek S, et al. Thrombopoietin inside the pulmonary vessels in patients with and without pulmonary hypertension. Platelets 2002; 13: 395–399
   PubMed Web of Science ®Google Scholar
• Harrison C N, Green A R. Essential thrombocythaemia. Best Pract Res Clin Haematol 2006; 19: 439–453
   PubMed Web of Science ®Google Scholar
• Jagroop I A, Daskalopoulou S S, Mikhailidis D P. Endothelin-1 and human platelets. Curr Vasc Pharmacol 2005; 3: 393–399
   PubMedGoogle Scholar
• Humbert M, Morrell N W, Archer S L, Stenmark K R, MacLean M R, Lang I M, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(Suppl S)13S–24S
   PubMed Web of Science ®Google Scholar
• Damas J K, Otterdal K, Yndestad A, Aass H, Solum N O, Froland S S, et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 2004; 110: 999–1005
   PubMed Web of Science ®Google Scholar
• Awabdy D, Bryan-Lluka L J, Wanstall J C. 5-Hydroxytryptamine and platelets: uptake and aggregation in hypoxic pulmonary hypertensive rats. Eur J Pharmacol 2003; 459: 1–7
   PubMed Web of Science ®Google Scholar
• Mandegar M, Fung Y C, Huang W, Remillard C V, Rubin L J, Yuan J X. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 2004; 68: 75–103
   PubMed Web of Science ®Google Scholar